# Trade Mark Journal No.2025/038 19 September 2025

## WO0000001874063 (35,38,42,44)

Office of origin: United States of America

Date of International Registration:25 April 2025
Date of designation in the UK: 25 April 2025

International priority date claimed: 20 November 2024 (United States of America) (98863148)

Class 35
  Administration of patient pharmaceutical reimbursement programs; administering a patient support and assistance program for obtaining reimbursement for prescription medicines.
Class 38
  Communication services, namely, transmission of information relating to pharmaceuticals, medicine, and medical conditions and diseases via all means of telecommunication including the Internet.
Class 42
  Providing online non-downloadable software that enables users to access educational and informational materials about medical conditions and diseases, pharmaceutical product and use information, resources for patient support and advocacy programs and treatment affordability programs, and accessing pharmaceuticals via a website; providing online non-downloadable software that enables users to access educational and informational materials about medical conditions and diseases, pharmaceutical product and use information, resources for patient support and advocacy programs and treatment affordability programs, and accessing pharmaceuticals via an interactive website; providing online non-downloadable software for users to access educational and informational materials about medical conditions and diseases, pharmaceutical product and use information, resources for patient support and advocacy programs and treatment affordability programs, and accessing pharmaceuticals.
Class 44
  Providing information in the field of rare diseases and treatment thereof; providing information in the fields of Prader-Willi syndrome, neurobehavioral diseases, metabolic diseases, endocrine diseases, and diseases characterized by hyperphagia, and the treatment thereof; providing medical information relating to disease awareness and disease management to improve understanding by patients and caregivers about pharmaceuticals, and providing medical information in the fields of medical products, access to medications and complying with instructions and directions for using medications and medical therapies, all the aforesaid provided through a pharmaceutical patient support program via a website.

Soleno Therapeutics, Inc.

Representative: John Paul Oleksiuk Cooley LLP, 1299 PENNSYLVANIA AVENUE, NW, SUITE 700,, ATTN: IP DOCKETING DEPARTMENT, Washington DC 20004-2400, UNITED STATES OF AMERICA